Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batroxobin + Anticoagulation in CVST
NCT04269954Phase 4Unknown
- Sponsor
- Capital Medical University
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of batroxobin in cerebral venous sinus thrombosis (CVST) (2 arms), sponsored by Capital Medical University. Primary endpoint: Percentage of Participants With Major Bleeding Event (MBE) at 2 weeks. Status: unknown.
02
Drugs
batroxobin
03
Conditions
cerebral venous sinus thrombosis (CVST)
Beyond the preview
Go deeper on NCT04269954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269954.